Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Jose Riestra Perez

Internal Medicine Bayamon, PR Medical Doctor

NPI 1184698797 CMS profile 325434

68 Calle Santa Cruz, Torre San Pablo Suite 904, Bayamon, PR 00961

Open in the dashboard

General payments

$261

12 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Jose Riestra Perez of Bayamon, PR is reported in the CMS Open Payments database as having received $261 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $21 1
2021 General $111 5
2020 General $66 3
2019 General $62 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Riestra Perez
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jose Riestra Perez were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jose Riestra Perez Internal Medicine median Middle half National median
2019 $62 $159 $48–$570 $163
2020 $66 $119 $33–$402 $114
2021 $111 $135 $37–$521 $132
2022 $21 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Sanofi-Aventis U.S. LLC $137 6 payments
  2. AbbVie, Inc. $41 2 payments
  3. Abbott Laboratories $22 1 payment
  4. Eli Lilly Export S.A. Puerto Rico Branch $20 1 payment
  5. Dexcom, Inc. $20 1 payment
  6. Merck Sharp & Dohme Corporation $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $261 12 payments
Products named General payments · program years 2019–2022
  1. SOLIQUA 100/33 Endocrine & Metabolic Diseases $71 3 payments
  2. SOLIQUA 100/33 Endocrinology $43 2 payments
  3. SYNTHROID $41 2 payments
  4. TOUJEO $23 1 payment
  5. FreeStyle Libre $22 1 payment
  6. TRULICITY $20 1 payment
  7. STEGLATRO $20 1 payment
  8. JANUVIA $20 1 payment
  9. JANUMET $20 1 payment
  10. DEXCOM G6 TRANSMITTER $20 1 payment
  11. Other $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,168

Median for Endocrinology: 1,959

Drug cost

$86,743

Median for Endocrinology: $890,201

Branded share of claims

54.5%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Synthroid Levothyroxine Sodium Brand 474 $51,980
Janumet Sitagliptin Phos/Metformin Hcl Brand 17 $11,303
Lantus Insulin Glargine,hum.Rec.Anlog Brand 48 $6,565
Humalog Kwikpen U-100 Insulin Lispro Brand 18 $4,594
Humalog Insulin Lispro Brand 24 $3,902
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 12 $1,275
Metoprolol Succinate Generic 57 $1,154
Glimepiride Generic 61 $725
Enalapril Maleate Generic 25 $545
Atorvastatin Calcium Generic 46 $527

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record